Table 1.
Distribution of ovarian cancer cases by estrogen-α (ERα) and progesterone (PR) receptor status in the Nurses’ Health Study, Nurses’ Health Study II and New England Case-Control Study
| All cases | ERα+a | ERα− | PR+a | PR− | |
|---|---|---|---|---|---|
| Total, n (%)b | 315 (100%) | 245 (78%) | 70 (22%) | 143 (45%) | 172 (55%) |
| Histology, n (%) | |||||
| Serous | 195 (62%) | 174 (71%) | 21 (30%) | 98 (69%) | 97 (56%) |
| Endometrioid | 51 (16%) | 43 (18%) | 8 (11%) | 30 (21%) | 21 (12%) |
| Mucinous | 16 (5%) | 8 (3%) | 8 (11%) | 5 (4%) | 11 (6%) |
| Clear cell | 25 (8%) | 4 (2%) | 21 (30%) | 1 (1%) | 24 (14%) |
| Other | 28 (9%) | 16 (7%) | 12 (17%) | 9 (6%) | 19 (11%) |
| Pc | <0.0001 | <0.0001 | |||
| Grade, n (%)d | |||||
| I | 26 (10%) | 24 (12%) | 2 (3%) | 20 (17%) | 6 (4%) |
| II | 54 (20%) | 40 (19%) | 14 (22%) | 32 (27%) | 22 (14%) |
| III | 190 (70%) | 143 (69%) | 47 (75%) | 66 (56%) | 124 (82%) |
| Pe | 0.14 | <0.0001 | |||
| Stage, n (%) | |||||
| I/II | 117 (37%) | 77 (31%) | 40 (57%) | 57 (40%) | 60 (35%) |
| III/IV | 198 (63%) | 168 (69%) | 30 (43%) | 86 (60%) | 112 (65%) |
| P | <0.0001 | 0.36 |
a
- Ovarian tumors were classified as ERα+ and PR+ if 1% or greater of cells stained positive
b
- Total N excludes 16 cases with unreadable ERα and PR staining and 10 cases scored as ERα−/PR+
c
- P-value calculated using Chi-square test comparing ERα+ vs. ERα− and PR+ vs. PR−
d
- 270 cases had data on grade
e
- P-value calculated using Chi-square test for trend